ClinicalTrials.gg
Active, not recruitingNCT07224347Updated Nov 4, 2025

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

An observational study in Functional Disability, Dementia and Heart Disease, sponsored by Anne Murray. Active, not recruiting at 36 sites in 2 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Anne Murray · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
19,114
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Enrollment
11th of 200
19,114 · median 200
Started
2019
with 57 others
Observational
200 of 1,051
51 open now
Primary completion
2026-04
later than 38 of 275 live
Registered
984th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 11th largest by enrollment of the 200 observational ones that give a count, is one of 58 that started in 2019, is one of 200 observational ones, reaches primary completion later than 38 of the 275 other live ones, and was the 984th registered.

Dementia

2,376 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

Read the detailed description

ASPREE-XT is a longitudinal, observational follow-on study of ASPREE participants.

The methodology of ASPREE-XT is based closely on ASPREE [ASPREE investigator group, 2013; www.aspree.org; McNeil et al. 2017]. Clinical, neurocognitive and physical function measurements, questionnaires for mood, quality of life, physical ability and collection of personal health, demographic and lifestyle details are the same in ASPREE-XT as those conducted and described for ASPREE.

Since ASPREE-XT is an observational study, the endpoints for ASPREE will be collected and adjudicated in a similar way for ASPREE-XT but will be referred to as ASPREE-XT Outcomes. These will not be divided into primary and secondary endpoints.

In 2018, participants were invited to enroll in ASPREE-XT. At the first ASPREE-XT study visit, or via mail, they were provided with an information sheet and consent form for the study Participants who wish to only be contacted by phone were provided with information and a consent form by mail with health and other study data collected by phone call.

03

Conditions studied

  • Functional Disability
  • Dementia
  • Heart Disease
  • Stroke
  • Cancer
  • Bleeding
  • Depression
  • Frailty

Keywords

  • Aspirin
  • Prevention
  • Healthy
  • Over 70 years old
  • ASPREE
  • Aspirin in Reducing Events in the Elderly
  • Australia
  • Functional Disability
  • Dementia
  • Heart Disease/ Stroke
  • Cancer
  • Bleeding
  • Frailty
  • Community-Dwelling
  • Older Adult
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Men and women recruited from the United States and Australia.

  • African American and Hispanic persons age 65 or older in the U.S.
  • Any person from another ethnic minority group and Caucasian persons age 70 or older
  • Willing and able to provide informed consent, and willing to accept the study requirements

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • African American and Hispanic persons age 65 or older
  • Any person from another ethnic minority group and Caucasian persons age 70 or older
  • Willing and able to provide , and willing to accept the study requirements

Exclusion criteria

Exclusion Criteria:

  • A history of a diagnosed cardiovascular event
  • A serious intercurrent illness likely to cause death within the next 5 years, such as terminal cancer or obstructive airways disease
  • A current or recurrent condition with a high risk of major bleeding, ex: cerebral aneurysm
  • Anemia
  • Absolute or allergy to aspirin
  • Current participation in a clinical trial
  • Current continuous use of aspirin or other anti- drug or anticoagulant for secondary prevention. People with previous use of aspirin for primary prevention may enter the trial, provided they agree to cease existing use of aspirin and understand that they may be subsequently randomly allocated to low dose aspirin or placebo.
  • A systolic blood pressure ≥180 mmHg and / or a diastolic blood pressure ≥105 mmHg
  • A history of dementia
  • Severe difficulty or an inability to perform any one of the 6 Katz ADLs
  • Non-compliance to taking pill
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
19,114 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Aspirin

    100 mg enteric-coated aspirin

  • Placebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Death from any cause or incident dementia or permanent physical disability.

    These categories of disability are defined, respectively, as a) all-cause mortality, b) the assessment of dementia by DSM-IV criteria or c) the onset of 'a lot of difficulty' or 'inability' to perform independently, any one of 6 Katz ADLs.

    Time frame: Planned 5-year time frame

07

Study locations

36 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Howard University
    Washington D.C., District of Columbia 20060, United States
  • Morehouse School of Medicine
    Atlanta, Georgia 30310, United States
  • Emory/ Atlanta VAMC
    Atlanta, Georgia 30322, United States
  • Rush Alzheimer's Disease Center
    Chicago, Illinois 60612, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • LSU Health Sciences- Shreveport
    Shreveport, Louisiana 71130, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • HealthPartners Research Institute
    Minneapolis, Minnesota 55425, United States
  • Phalen Village Clinic
    Saint Paul, Minnesota 55106, United States
  • Wake Forest University Baptist Medical Center
    Greensboro, North Carolina 27408, United States
  • The Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27834, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • University of Pittsburgh Health Sciences Research Center
    Pittsburgh, Pennsylvania 15260, United States
  • Kent County Memorial Hospital
    Pawtucket, Rhode Island 02860, United States
  • University of Tennessee Health Science Center
    Memphis, Tennessee 38105, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • Regional Academic Health Center
    Harlingen, Texas 78550, United States
  • UT Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Clinical Trials Unit, The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Illawarra Health and Medical Research Institute, University of Wollongong
    Wollongong, New South Wales 2522, Australia
  • Discipline of General Practice, School of Population Health, University of Adelaide
    Adelaide, South Australia 5005, Australia
  • Greater Green Triangle University
    Mount Gambier, South Australia 5290, Australia
  • University of Tasmania Rural Clinical School
    Burnie, Tasmania 7320, Australia
  • The Menzies Institute for Medical Research, University of Tasmania
    Hobart, Tasmania 7000, Australia
  • University of Tasmania Newnham Campus
    Launceston, Tasmania 7250, Australia
  • Bendigo Regional Clinical School
    Bendigo, Victoria 3550, Australia
  • Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Monash Mildura Regional Clinical School
    Mildura, Victoria 3500, Australia
  • University of Ballarat
    Mount Helen, Victoria 3350, Australia
  • Monash Gippsland Regional Clinical School
    Traralgon, Victoria 3844, Australia
  • The South West Alliance of Rural Health (SWARH)
    Warrnambool, Victoria 3280, Australia
  • Gateway Community Health
    Wodonga, Victoria 3690, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Apr 2026, 81 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 81 months is close to that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 4, 2025
StartActual
Jul 15, 2019
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07224347
Lead sponsor
Anne Murray
Collaborators
National Health and Medical Research Council, Australia, Bayer, Monash University, Berman Center for Outcomes and Clinical Research, National Institute on Aging (NIA), National Cancer Institute (NCI)
Responsible party
Anne Murray (Principal Investigator, Staff Endocrinologist, Hennepin Healthcare Research Institute) — Sponsor-investigator
First posted
Nov 4, 2025
Start date
Jul 15, 2019
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Nov 4, 2025

Study contacts

Anne Murray, MD, MSc
principal investigator · Berman Center for Outcomes and Clinical Research
John McNeil, MBBS, PHD
principal investigator · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion